Drugmakers forge ahead with immunotherapies

Large drugmakers and startup biotechnology companies are developing therapies that harness the body's immune system to recognize and attack tumor cells, and some drugs, such as Bristol-Myers Squibb's melanoma drug Yervoy, have shown promising results. "That these agents can produce a long-term stable response in multiple tumor types is a whole new approach to treating cancer," said Yale Cancer Center chief of medical oncology Roy Herbst. The technology could transform the way cancer is treated and refill dry drugmaker pipelines, analysts say.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX